Calidi Biotherapeutics Inc (CLDI) concluded trading on Thursady at a closing price of $0.99, with 6.7 million shares of worth about $6.63 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -89.13% during that period and on Thursady the price saw a gain of about 52.49%. Currently the company’s common shares owned by public are about 35.49M shares, out of which, 20.53M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of 85.34% in past 5 days and over the past one month there was a price change of -0.88%. Year-to-date (YTD), CLDI shares are showing a performance of -34.36% which decreased to -90.01% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.48 but also hit the highest price of $13.79 during that period. The average intraday trading volume for Calidi Biotherapeutics Inc shares is 85.84K. The stock is currently trading 37.83% above its 20-day simple moving average (SMA20), while that difference is down -19.83% for SMA50 and it goes to -82.24% lower than SMA200.
Calidi Biotherapeutics Inc (AMEX: CLDI) currently have 35.49M outstanding shares and institutions hold larger chunk of about 5.71% of that.
The stock has a current market capitalization of $35.18M and its 3Y-monthly beta is at 0.32. It has posted earnings per share of -$1.06 in the same period. It has Quick Ratio of 1.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLDI, volatility over the week remained 43.42% while standing at 22.63% over the month.
Analysts are in expectations that Calidi Biotherapeutics Inc (CLDI) stock would likely to be making an EPS of -$0.2 in the current quarter, while forecast for next quarter EPS is -$0.2 and it is -$0.76 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.21 which is -$0.2 at the higher side of the target for the same.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on November 22, 2023 offering a Buy rating for the stock and assigned a target price of $11 to it. Coverage by Robert W. Baird stated Calidi Biotherapeutics Inc (CLDI) stock as an Outperform in their note to investors on October 09, 2023, suggesting a price target of $9 for the stock.
